Review Papers Claim by Claim

Critical appraisal (concise)

1. Method heterogeneity & databases: The review correctly flags that DNA extraction kits, ITS1 vs ITS2 primer biases, and reference database incompleteness drive between-study variation; this undermines cross-study meta-analysis unless controlled for Zhang et al. (methods heterogeneity).
2. Cause vs correlation: Most human studies cited are cross‑sectional; causal claims are speculative and Zhang et al. appropriately call for longitudinal/interventional work (antifungals, defined fungal colonization, FMT with fungal profiling) to test causality Iliev et al. 2012 (Dectin-1 mechanistic evidence).
3. Transient vs resident fungi: Zhang et al. emphasize that dietary/environmental 'passing-through' fungi (e.g., edible mushrooms) can confound fecal surveys and that mucosa-associated communities are more stable — a necessary distinction for mechanistic inference Zhang et al. (fecal vs mucosa).
4. Animal evidence is informative but not sufficient: Zhang et al. cite murine models showing fungal modulation (Malassezia, Candida) of inflammation and metabolic phenotypes; these are mechanistic but may not translate quantitatively to humans due to host-specific fungal ecology (note: see more recent rodent surveys) Rodent mycobiome review.
5. Therapeutics: promise, not practice: Zhang et al. highlight antifungals, fungal probiotics (S. boulardii), and FMT as potential interventions but stress limited RCT evidence and safety/selection concerns; this restrained position is scientifically appropriate Zhang et al. (therapeutics).

Concrete ways to advance the field (per Zhang et al. + additions)

• Adopt standardized extraction and ITS primer sets (or report dual-ITS1/ITS2 data) and include spike-in controls for extraction efficiency Zhang et al. (standardization).
• Use curated gut fungal reference databases (shotgun-validated, e.g., FungiGutDB-style resources) to lower false positives in metagenomics FungiGutDB (curated gut fungal DB).
• Design pre-registered longitudinal and interventional human studies (antifungal RCTs, targeted fungal colonization in gnotobiotic humanized mice, FMT with donor mycobiome profiling) to test causality — Zhang et al. call for this and so do mechanistic studies such as Dectin-1/CARD9 work Dectin-1 mechanistic study.

Paper limitations and blindspots

• As a narrative review it risks selection bias (authors selected 103 papers) and cannot quantify effect sizes or heterogeneity across cohorts Zhang et al. (scope/limitations).
• Rapidly evolving computational resources (curated gut fungal databases, improved metagenomic classifiers) post-date many cited studies — re-analyses with modern pipelines could change reported taxa associations FungiGutDB (method improvement).

What would alter the review's conclusions?

• Robust RCTs showing that targeted antifungal or fungal-probiotic interventions reproducibly change disease outcomes (IBD flare rates, CRC progression biomarkers, metabolic endpoints) would move associations toward causality (the authors note this explicitly) Zhang et al. (need RCTs).
• Conversely, large, well-controlled longitudinal cohorts showing stable mycobiome signatures accounting for confounders (diet, medications) and predicting disease onset would strengthen the case for causal involvement.